Collagen's role in skin cancer

October 23, 2015
Collagen’s role in skin cancer
Credit: Kome (Flickr)

Type VII collagen is an important protein that helps hold the skin together. Patients with a severe skin condition known as recessive dystrophic epidermolysis bullosa (RDEB) have genetic mutations that lead to reductions in type VII collagen, causing blistering following minor trauma.

Young adults with RDEB go on to develop aggressive, , a type of cancer which is fatal in two thirds by the age of 45.

The study, published in the Journal of the National Cancer Institute, now shows that in both RDEB scarred skin and RDEB tumours, type VII collagen is an important regulator of blood vessel formation – a major mechanism in tumour development.

This study is important for patients with RDEB as it suggests that using non-mutated type VII collagen as a treatment may reverse formation, and potentially prevent tumour development.

Lead researcher Professor Edel O'Toole from the Blizard Institute at QMUL said: "In addition to the potential benefits for RDEB patients, we now know that type VII collagen may play an important role in suppressing tumour formation in skin. This may also be relevant in other organs where type VII collagen is present, such as bowel and oral mucosa."

The researchers grew skin cancer cells in the lab and engineered them to have a loss of type VII collagen. They then built 3D cellular models from human squamous cell carcinoma cells and observed the number of blood vessels that developed.

The team found that that loss of type VII collagen in cell lines and tumours from patients led to increased . Their findings were then confirmed in skin tumours from RDEB patients and the general population.

Explore further: Quality control for adult stem cell treatment

More information: V. L. Martins et al. Suppression of TGF and Angiogenesis by Type VII Collagen in Cutaneous SCC , Journal of the National Cancer Institute (2015). DOI: 10.1093/jnci/djv293

Related Stories

Quality control for adult stem cell treatment

February 27, 2015
A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected ...

Stem cell therapy for inherited skin blistering

May 26, 2015
Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was ...

Fractional, ablative er:YAG laser akin for skin resurfacing

November 10, 2012
(HealthDay)—Multiple sessions of fractional laser treatment with erbium:yttrium-aluminum-garnet (Er:YAG) for facial resurfacing are comparable to a single ablative Er:YAG laser treatment, according to a small study published ...

Recommended for you

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.